Successful hematopoietic reconstitution by unrelated donor cord blood transplantation in children with Fanconi anemia: report of 3 cases

J Pediatr Hematol Oncol. 2014 Nov;36(8):e553-5. doi: 10.1097/MPH.0000000000000215.

Abstract

To potentially reduce late effects of malignancy and chronic graft-versus-host disease in patients with Fanconi anemia, 3 patients received unmanipulated umbilical cord blood grafts with 0 or 1 HLA antigen mismatch. The conditioning regimen consisted of fludarabine (30 mg/m/d) for 6 days, cyclophosphamide (60 mg/kg/d) for 2 days, and rabbit antithymocyte globulin (ATG) (2.5 mg/kg/d) for 3 days. Radiation was not used in the preparative regimen. None of the patients had significant conditioning-related toxicity. All were engrafted within 10 to 19 days. All patients are well with stable or full donor chimerism after a median follow-up of 64 months (range, 13 to 69 mo).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antilymphocyte Serum / administration & dosage
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Child, Preschool
  • Chronic Disease
  • Cord Blood Stem Cell Transplantation / adverse effects*
  • Cord Blood Stem Cell Transplantation / methods*
  • Cyclophosphamide / administration & dosage
  • Fanconi Anemia / therapy*
  • Graft vs Host Disease / therapy*
  • Hematopoiesis / drug effects*
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Infant
  • Male
  • Myeloablative Agonists / administration & dosage
  • Rabbits
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Antilymphocyte Serum
  • Antineoplastic Agents, Alkylating
  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Cyclophosphamide
  • Vidarabine
  • fludarabine